Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2025 05:00 ET | Source: OBI Pharma Inc.

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

TAIPEI, Taiwan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-902, an antibody-drug...
September 18, 2023 08:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE...
July 10, 2023 05:00 ET | Source: Spinogenix, Inc.

Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it...
July 11, 2022 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...